Tongshu Gene Secures Over 100 Million RMB in Series D Funding
Tongshu Gene recently completed a Series D funding round of over 100 million RMB ($14 million) led by Wuxi Liangxi Sci-Tech Innovation Industry Investment Fund (managed by Bohua Capital) and followed by Jiangsu Jiandao Venture Capital, to support its ongoing R&D efforts, production expansion, market channel development, and brand enhancement.
With seven years of expertise in genetic testing, Tongshu Gene follows a “product + service” strategy centered around hospitals. The company focuses on clinical needs, developing a range of IVD diagnostic technologies with high technical barriers. Tongshu has built a comprehensive technology platform with deep coverage in the in-vitro diagnostics (IVD) space. Guided by its multi-platform innovation strategy, the company has developed IVD products with unique technological advantages across various fields, including first- and second-generation sequencing, quantitative PCR, and CRISPR. In January 2021, Tongshu’s independently developed Microsatellite Instability (MSI) detection kit received China’s first Class III medical device registration certificate for MSI detection. This kit offers a competitive edge in diagnosing 17 types of cancers, including gastric, colorectal, and breast cancers. In March 2024, Tongshu launched a full-site osimertinib companion diagnostic kit, filling a critical gap in the domestic market. The kit employs a non-ARMS PCR method combined with proprietary MASS technology to accurately identify EGFR mutations, providing reliable guidance for personalized lung cancer treatment.
Firmly rooted in the domestic market, Tongshu Gene has actively expanded its sales channels, now serving over 1,000 hospitals across more than 30 provinces, municipalities, and autonomous regions in China. After years of refining its sales strategies, the company’s team leads the industry with superior performance. Over the past seven years, Tongshu has achieved rapid revenue growth, solidifying its position among the top-tier companies in the field. As more flagship products receive regulatory approval, Tongshu Gene is poised to become a leader in China’s trillion-yuan precision medicine oncology market.
